Skip to contentE
Ernexa Therapeutics Inc.
E
ERNAWErnexa Therapeutics Inc. Released May 10, 2012, after the close
10-Q filed May 11, 2012, 41 days after period end · 0001019687-12-001718
Q1 2012 · 10-Q
Revenue$6.07M$6.07M+1.1% vs Q1 2011−0.6% vs Q4 2011 Net Income-$1.05M-$1.05M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR
N/M vs Q4 2011
EPS Diluted-$0.02-$0.02N/M vs Q1 2011N/M vs Q4 2011 Operating Income-$997,000N/M Operating Cash Flow$255,000−71.8% Free Cash Flowderived-$150,000N/M Margins · derivedOperating margin-16.4%−7.8 pt vs Q1 2011
Net margin-17.2%−7.9 pt vs Q1 2011
ended Mar 31, 2012 · filed May 11, 2012 · 41 d after period end